J. Strosberg, G. El-Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 376, 125–135 (2017)

Article  PubMed  PubMed Central  Google Scholar 

J. Del Rivero, K. Perez, E.B. Kennedy, E.S. Mittra, N. Vijayvergia, J. Arshad et al. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. J Clin Oncol 41, 5049–5067 (2023)

Article  PubMed  Google Scholar 

T. Brabander, W.A. van der Zwan, J.J.M. Teunissen, B.L.R. Kam, R.A. Feelders, W.W. de Herder, et al. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.Clin Cancer Res 23, 4617–4624 (2017)

W.T. Zandee, T. Brabander, A. Blažević, N.S. Minczeles, R.A. Feelders, W.W. de Herder et al. Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome. J Clin Endocrinol Metab 106, e3665–e3672 (2021)

Article  PubMed  PubMed Central  Google Scholar 

M. Albertelli, A. Dotto, C. Di Dato, P. Malandrino, R. Modica, A. Versari et al. PRRT: identikit of the perfect patient. Rev Endocr Metab Disord 22, 563–579 (2021)

Article  PubMed  Google Scholar 

S. Ezziddin, L. Adler, A. Sabet, T.D. Pöppel, F. Grabellus, A. Yüce et al. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system. J Nucl Med 55, 1260–1266 (2014)

Article  PubMed  Google Scholar 

S. Ezziddin, M. Attassi, C.J. Yong-Hing, H. Ahmadzadehfar, W. Willinek, F. Grünwald et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med 55, 183–190 (2014)

Article  PubMed  Google Scholar 

D. Feijtel, G.N. Doeswijk, N.S. Verkaik, J.C. Haeck, D. Chicco, C. Angotti et al. Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response. Theranostics 11, 491–505 (2021)

Article  PubMed  PubMed Central  Google Scholar 

G. Tamborino, J. Nonnekens, M. De Saint-Hubert, L. Struelens, D. Feijtel, M. de Jong et al. Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and In Vivo Survival. J Nucl Med 63, 100–107 (2022)

Article  PubMed  PubMed Central  Google Scholar 

Z. Yang, L.H. Tang, D.S. Klimstra, Effect of Tumor Heterogeneity on the Assessment of Ki67 Labeling Index in Well-differentiated Neuroendocrine Tumors Metastatic to the Liver: Implications for Prognostic Stratification. American Journal of Surgical Pathology 35, 853–860 (2011)

Article  PubMed  Google Scholar 

L. Al Mansour, L. De Mestier, M. Haissaguerre, P. Afchain, J. Hadoux, T. Lecomte et al. Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network. J Nucl Med 65, 258–263 (2024)

Article  PubMed  Google Scholar 

J.R. Strosberg, T. Al-Toubah, E. Pellè, J. Smith, M. Haider, T. Hutchinson et al. Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy. J Nucl Med 62, 69–72 (2021)

Article  PubMed  Google Scholar 

I.D. Nagtegaal, R.D. Odze, D. Klimstra, V. Paradis, M. Rugge, P. Schirmacher et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 76, 182–188 (2020)

Article  PubMed  Google Scholar 

A. Chaban, J. Brosh-Lentz, Y. Song, V. Dinkel, L. Bodei, W. Weber, Optimized segmentation of neuroendocrine tumor lesions on somatostatin receptor PET/CT imaging for therapy response assessment. EANM’23 Abstract Book Congress Sep 9-13, 2023. Eur J Nucl Med Mol Imaging 50, 1–898 (2023). Suppl 1

Google Scholar 

R.P. Reddy, C. Ross Schmidtlein, R.G. Giancipoli, A. Mauguen, D. LaFontaine, H. Schoder et al. The Quest for an Accurate Functional Tumor Volume with 68Ga-DOTATATE PET/CT. J Nucl Med 63, 1027–1032 (2022)

Article  PubMed  PubMed Central  Google Scholar 

B. Foster, U. Bagci, A. Mansoor, Z. Xu, D.J. Mollura, A review on segmentation of positron emission tomography images. Comput Biol Med 50, 76–96 (2014)

Article  PubMed  Google Scholar 

A. Gafita, L. Djaileb, I. Rauscher, W.P. Fendler, B. Hadaschik, S.P. Rowe et al. Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer. Radiology 308, e222148 (2023)

Article  PubMed  Google Scholar 

A. Gafita, M. Bieth, M. Krönke, G. Tetteh, F. Navarro, H. Wang et al. qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET/CT. J Nucl Med 60, 1277–1283 (2019)

Article  PubMed  PubMed Central  Google Scholar 

R.L. Wahl, H. Jacene, Y. Kasamon, M.A. Lodge, From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50, 122S–150SS (2009). Suppl 1

Article  PubMed  Google Scholar 

M. Mileva, G. Marin, H. Levillain, C. Artigas, C. Van Bogaert, C. Marin et al. Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study. J Nucl Med 65, 236–244 (2024)

Article  PubMed  Google Scholar 

Maccauro M., Cuomo M., Bauckneht M., Bagnalasta M., Mazzaglia S., Scalorbi F., et al. The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [(177)Lu]Lu-DOTATATE. Eur J Nucl Med Mol Imaging. 2024;52:291–304.

K. Hebert, L. Santoro, M. Monnier, F. Castan, I. Berkane, E. Assénat et al. Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine. J Nucl Med 65, 923–930 (2024)

Article  PubMed  PubMed Central  Google Scholar 

C. Chiapponi, N. Lürssen, B. Cremer, R. Wahba, U. Drebber, M. Faust et al. Peptide receptor radionuclide therapy as a two-step strategy for initially unresectable liver disease from neuroendocrine tumors: a single-center experience. Endocrine 70(1), 187–193 (2020). Oct

Article  PubMed  Google Scholar 

M. Maccauro, G.A. Follacchio, C. Spreafico, J. Coppa, E. Seregni Safety and Efficacy of Combined Peptide Receptor Radionuclide Therapy and Liver Selective Internal Radiation Therapy in a Patient With Metastatic Neuroendocrine Tumor. Clin Nucl Med 44, e286–e288 (2019)

Article  PubMed  Google Scholar 

S. Ezziddin, A. Sabet, F. Heinemann, C.J. Yong-Hing, H. Ahmadzadehfar, S. Guhlke et al. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. J Nucl Med 52, 1197–1203 (2011)

Article  PubMed  Google Scholar 

R. Halperin, A. Tirosh, Mid-Treatment Response to 177-Lutetium Dotatate Predicts Overall Outcome in Patients With Advanced Neuroendocrine Tumors. JCO Oncol Pract 27, OP2300789 (2024)

Google Scholar 

V. Santoro-Fernandes, B. Schott, A. Deatsch, Q. Keigley, T. Francken, R. Iyer et al. Models using comprehensive, lesion-level, longitudinal [(68)Ga]Ga-DOTA-TATE PET-derived features lead to superior outcome prediction in neuroendocrine tumor patients treated with [(177)Lu]Lu-DOTA-TATE. Eur J Nucl Med Mol Imaging 51, 3428–3439 (2024)

Article  PubMed  Google Scholar